Physician profile
Saurin Akshay Chokshi
NPI 1043576952
$85,896.44
in general payments reported to CMS, 2019-2025
31 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,715 · 2020: $73.49 · 2021: $129 · 2022: $176 · 2023: $9,245 · 2024: $25K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $35K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $11K · Consulting Fee: $7,750 · Food and Beverage: $3,739 · Honoraria: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $35,477.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,450.00 |
| Travel and Lodging | $11,386.54 |
| Consulting Fee | $7,750.00 |
| Food and Beverage | $3,738.89 |
| Honoraria | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $60,477.51 | 2022-2025 | Cabometyx |
| Taiho Oncology, INC. | $16,997.98 | 2025 | |
| Novartis Pharmaceuticals Corporation | $2,548.10 | 2019-2025 | |
| Beone Medicines USA, INC. | $2,041.19 | 2025 | Tevimbra |
| F. Hoffmann-La Roche Ag | $1,937.79 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $332.14 | 2021-2025 | |
| Genentech USA, INC. | $233.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $229.88 | 2024-2025 | Opdivo, Krazati, Augtyro |
| Pfizer INC. | $216.81 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $180.03 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Medtronic, INC. | $77.39 | 2022-2023 | Signia |
| Novocure INC. | $73.49 | 2020 | |
| Amgen INC. | $70.75 | 2019-2022 | |
| Astellas Pharma US INC | $68.45 | 2025 | Vyloy |
| Janssen Scientific Affairs, LLC | $61.71 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $49.34 | 2023-2024 | Trodelvy |
| Celgene Corporation | $37.35 | 2019-2023 | Opdualag |
| Glaxosmithkline, LLC. | $27.81 | 2025 | Jemperli, Zejula |
| Lexicon Pharmaceuticals, INC. | $25.00 | 2019 | |
| Incyte Corporation | $23.28 | 2025 | Jakafi |
| Daiichi Sankyo INC. | $22.11 | 2025 | Enhertu |
| Janssen Biotech, INC. | $21.85 | 2025 | Erleada, Balversa, Akeega |
| Beigene USA, INC. | $21.38 | 2025 | Brukinsa |
| Integra Lifesciences Corporation | $20.57 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Array Biopharma INC | $20.40 | 2025 | Braftovi, Mektovi, Tukysa |
| Eisai INC. | $20.20 | 2019 | |
| Puma Biotechnology, INC. | $18.22 | 2024 | |
| Acrotech Biopharma INC. | $15.87 | 2024 | Beleodaq |
| Tersera Therapeutics LLC | $13.28 | 2023 | Zoladex |
| Janssen Pharmaceuticals, INC | $13.06 | 2023 | Xarelto |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurin Chokshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.